RECRUITING

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

Talk to us

Conditions

Pediatric Anesthesiapediatricanesthesiadexmedetomidine

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.

Official Title

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

Quick Facts

Study Start:2018-02-18
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03384563

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Month to 36 Months
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation
  2. 2. History of difficult intubation or ventilation
  3. 3. Airway malformation
  4. 4. Congenital heart disease
  5. 5. Cardiac arrhythmias
  6. 6. Central nervous system disease, including developmental delay, cerebral palsy, or seizure disorder
  7. 7. History of or family history of malignant hyperthermia
  8. 8. Electrolyte disorders
  9. 9. Gastrointestinal disease
  10. 10. Hepatic dysfunction
  11. 11. Renal dysfunction
  12. 12. Metabolic disease, such as diabetes
  13. 13. Obesity, defined as a body mass index greater than the 95% percentile for age
  14. 14. Preterm infant (less than 37 weeks gestational age) 15. Use of any medications (anticonvulsants, opioids, benzodiazepines, antibiotics, antihistamines drugs that induce hepatic enzymes) that may affect MAC.

Contacts and Locations

Study Contact

Margaret Owens-Stuberfield
CONTACT
832-824-5800
owensstu@bcm.edu

Principal Investigator

Rahul Baijal, MD
PRINCIPAL_INVESTIGATOR
Baylor College of Medicine

Study Locations (Sites)

Texas Children's Hospital
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: Baylor College of Medicine

  • Rahul Baijal, MD, PRINCIPAL_INVESTIGATOR, Baylor College of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-02-18
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2018-02-18
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • pediatric
  • anesthesia
  • dexmedetomidine

Additional Relevant MeSH Terms

  • Pediatric Anesthesia